ResearchPod Summary
Substance use disorders (SUDs) remain a major global health crisis, yet current neurobiological models struggle to capture the complex, human-specific genetic and developmental pathways driving addiction. Traditional models—including immortalized cell lines, rodent studies, and static postmortem human brain tissue—often fail to recapitulate the dynamic circuit-level interactions and patient-specific genetic vulnerabilities inherent in substance use. Recent advances in human pluripotent stem cell (hPSC) technologies offer a transformative solution, enabling researchers to study human neurons, glia, and organ-level architectures in highly controlled in vitro environments.
The review categorizes stem cell-based models into four primary tiers:
These stem cell systems have already provided novel mechanistic findings. For instance, studies have shown that chronic opioid exposure in midbrain organoids disrupts neuronal subtype specification, while alcohol exposure in cortical organoids impairs synaptogenesis and triggers epigenetic remodeling via the Hippo signaling pathway. Furthermore, organoid-on-a-chip models have successfully replicated cardiotoxic responses to stimulants and modeled respiratory depression associated with opioid overdose. By integrating multi-omics with functional readouts, these platforms are now being used to identify candidate biomarkers and potential targets for personalized pharmacological interventions, bridging the gap between genetic association and clinical therapy.
Stem cell-based models effectively address the translational barriers of traditional neuroscience. By recapitulating the developmental trajectory of addiction at a cellular level, these platforms offer a powerful path to move beyond simple correlation, allowing researchers to causally link genetic risks to specific neural vulnerabilities. While challenges regarding cost, standardization, and maturation persist, they represent the most promising avenue for developing precise, patient-tailored therapeutic innovations in addiction pharmacology.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.